User:Mr. Ibrahem/Gefitinib

Mr. Ibrahem/Gefitinib
Clinical data
Pronunciation	/ɡɛˈfɪtɪnɪb/
Trade names	Iressa, others
Other names	ZD1839
AHFS/Drugs.com	Monograph
MedlinePlus	a607002
License data	EU EMA: by INN; US DailyMed: Gefitinib;
Pregnancy; category	AU: C; ;
Routes of; administration	By mouth
Drug class	Tyrosine kinase inhibitor (EGFR inhibitor)
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	59% (by mouth)
Protein binding	90%
Metabolism	Liver (mainly CYP3A4)
Elimination half-life	6–49 hours
Excretion	Feces
Identifiers
	IUPAC name N-(3-chloro-4-fluoro-phenyl)-7-methoxy-; 6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;
Chemical and physical data
Formula	C22H24ClFN4O3
Molar mass	446.91 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1COCCN1CCCOc2c(OC)cc3ncnc(c3c2)Nc4cc(Cl)c(F)cc4;
	InChI InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27) ; Key:XGALLCVXEZPNRQ-UHFFFAOYSA-N ;
	(verify)

Gefitinib, sold under the brand name Iressa, is a medication used to treat non-small cell lung cancer (NSCLC).^[1] Specifically it is used in cases which have certain mutations of the epidermal growth factor receptor.^[2] It is taken by mouth.^[1]

Common side effects include rash, diarrhea, nausea, fever, mouth inflammation, eye problems, liver problems, and kidney problems.^[1] Other side effects may include interstitial lung disease and infertility.^[1] Use in pregnancy may harm the baby.^[1] It is a tyrosine kinase inhibitor and EGFR inhibitor.^[1]

Gefitinib was approved for medical use in the United States in 2003 and Europe in 2009.^[1]^[3] It is on the World Health Organization's List of Essential Medicines as an alternative to erlotinib.^[4] It is available as a generic medication.^[2] In the United Kingdom a month costs the NHS about £2,200 as of 2021.^[2] This amount in the United States costs about 8,100 USD.^[5]

References[edit]

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j "Gefitinib Monograph for Professionals". Drugs.com. Archived from the original on 5 November 2021. Retrieved 3 December 2021.
^ ^a ^b ^c ^d BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1027. ISBN 978-0857114105.
^ "Iressa". Archived from the original on 5 November 2021. Retrieved 3 December 2021.
^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
^ "Iressa Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 17 May 2016. Retrieved 3 December 2021.